AJP - GI Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Gastrointest Liver Physiol 297: G98-G106, 2009. First published April 23, 2009; doi:10.1152/ajpgi.00045.2009
0193-1857/09 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
297/1/G98    most recent
00045.2009v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Herath, C. B.
Right arrow Articles by Angus, P. W.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herath, C. B.
Right arrow Articles by Angus, P. W.

LIVER AND BILIARY TRACT

Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2

Chandana B. Herath,1 John S. Lubel,1 Zhiyuan Jia,1 Elena Velkoska,1 David Casley,1 Lindsay Brown,2 Chris Tikellis,3 Louise M. Burrell,1 and Peter W. Angus1

1Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria; 2School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland; and 3Baker Heart Research Institute, Melbourne, Victoria, Australia

Submitted 2 February 2009 ; accepted in final form 15 April 2009

Angiotensin converting enzyme (ACE) 2 activity and angiotensin-(1-7) [Ang-(1-7)] levels are increased in experimental cirrhosis; however, the pathways of hepatic Ang-(1-7) production have not been studied. This study investigated the role of ACE2, ACE, and neutral endopeptidase (NEP) in the hepatic formation of Ang-(1-7) from angiotensin I (Ang I) and Ang II and their effects on portal resistance. Ang I or Ang II were administered to rat bile duct ligated (BDL) and control livers alone and in combination with the ACE inhibitor lisinopril, the ACE and NEP inhibitor omapatrilat, or the ACE2 inhibitor MLN4760 (n = 5 per group). BDL markedly upregulated ACE, ACE2, and NEP. Ang-(1-7) was produced from Ang II in healthy and in BDL livers and was increased following ACE inhibition and decreased by ACE2 inhibition. In contrast, Ang-(1-7) production from Ang I was minimal and not affected by ACE or NEP inhibition. Surprisingly, ACE2 inhibition in BDLs dramatically increased Ang-(1-7) production from Ang I, an effect abolished by ACE2/NEP inhibition. Ang II and Ang I induced greater portal pressure increases in BDL livers than controls. The effects of Ang I were closely correlated with Ang II production and were strongly attenuated by both ACE and ACE/NEP inhibition. These findings show that the major substrate for hepatic production of Ang-(1-7) is Ang II and this is catalyzed by ACE2. Ang I is largely converted to Ang II by ACE, and net conversion of Ang I to Ang-(1-7) is small. NEP has the ability to generate large amounts of Ang-(1-7) in the BDL liver from Ang I only when ACE2 activity is greatly decreased or inhibited.

hepatic fibrosis; neutral endopeptidase; hepatic resistance; angiotensin peptide metabolism; angiotensin converting enzyme



Address for reprint requests and other correspondence: C. B. Herath, Dept. of Medicine, The Univ. of Melbourne, Austin Repatriation Hospital, Heidelberg Heights, Victoria, Australia (e-mail: cherath{at}unimelb.edu.au)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.